Back to results
US 2006/0040893 A1Published application
Immunomodulatory methods using oligosaccharides
OwnerDonald Harn, Palanivel Velupillaiinventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerDonald Harn, Palanivel Velupillaiinventors
Estimating the term…
Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokine that regulates development of a T helper type 1 or T helper type 2 response is modulated. In one embodiment, the agent is a stimulatory form of a compound comprising a Lewis antigen, such as a Lewisy, Lewisx or Lewisa oligosaccharide, or a derivative thereof. In another embodiment, the agent is an inhibitory form of a compound comprising a Lewis antigen, such as a Lewisy, Lewisx or Lewisa oligosaccharide, or a derivative thereof. In various embodiments, the immune cell is a human immune cell, a macrophage or a T cell. Pharmaceutical compositions for modulating immune responses are also provided.
An immunomodulatory method comprising contacting a human immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the human immune cell such that production by the human immune cell of at least one cytokine that regulates development of a T helper type 1 (Th1 ) or T helper type 2 (Th2) response is modulated.
(canceled)
5-6. (canceled)
9-12. (canceled)
17-22. (canceled)
24-28. (canceled)
30-35. (canceled)
37-41. (canceled)
A pharmaceutical composition comprising an agent that modulates interaction of a compound comprising a Lewis antigen with human immune cells of a human subject in an amount sufficient to modulate production by the human immune cells of at least one cytokine that regulates development of a T helper type 1 (Th1) or a T helper type 2 (Th2) response when the agent is administered to the human subject, and a pharmaceutically acceptable carrier.
46-47. (canceled)
50-54. (canceled)
A pharmaceutical composition comprising a conjugate of a Lewis antigen, or derivative thereof, and a carrier molecule, such that the Lewis antigen, or derivative thereof, comprises 10-25% of the conjugate by weight, in an amount sufficient to stimulate production of at least one cytokine that regulates development of a T helper type 1 (Th1) or a T helper type 2 (Th2) response when the agent is administered to the subject, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.